Post hoc analysis of phase 3 trial shows benefit regardless of BRCA status.
ONCOLOGY
Fully funded by 
Content independently selected
-
Ovarian cancer: maintenance niraparib benefits partial chemotherapy responders -
Ovarian cancer: add-on trebananib fails to delay progression in phase 3 Data from the multinational TRINOVA-3 trial.
-
Tubal ligation is not associated with early natural menopause Surgical sterilization is one of the most common methods of contraception in the US.
-
Ovarian cancer: intraperitoneal chemotherapy ineffective in definitive trial Intraperitoneal administration shows no survival advantage, increases toxicity in GOG-252.
-
Niraparib shows activity in heavily pretreated ovarian cancer Phase 2 QUADRA shows benefit extends to HRD-positive platinum-sensitive disease.
-
The study was carried out by the Cancer Research UK Institute at the University of Manchester.
-
LION: lymphadenectomy fails to up OS in advanced ovarian cancer Higher complications were reported after complete macroscopic resection.
-
Relapsed ovarian cancer: cediranib/olaparib combo extends PFS Phase 2 data show effect is driven by subset without a known BRCA mutation.
-
The novel Radiomic Prognostic Vector has been developed by researchers at Imperial College London and the University of Melbourne.
-
USPSTF: draft supports screening for BRCA risk in primary care A positive screen warrants genetic counseling and potential genetic testing.
-
Heavily treated ovarian cancer: avelumab does well in phase 1b JAVELIN Responses were irrespective of PD-L1 and BRCA status.
-
Ovarian cysts: observation a safe alternative to surgery in IOTA5 20% of masses resolve spontaneously within 2 years.
-
Results from the International Ovarian Tumor Analysis Phase 5 (IOTA5) study, the largest of its kind to date.
-
Breastfeeding may protect against ovarian cancer for 30+ years Breastfeeding for as little as 3 months shows protective effect.